Unilife — Q1 FY2013 Earnings Presentation
20 slides from Unilife's earnings presentation, Nov 9, 2012
Slide 1: 1st Quarter Earnings Call
1st Quarter Earnings Call November 8, 2012 NASDAQ (UNIS) and ASX (UNS) Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo
Slide 3: Welcome
Welcome All fundamental areas of Unilife remain fully on track Today's announcement for Unilife bolus injector platform Commercial discussions continue to advance favorably Upcoming supply contracts and clinical development agreements Favorable revenue from multiple programs with multiple customers
Slide 4: Securing an ATM Facility
Securing an ATM Facility At-The-Market (ATM) facility with Cantor Fitzgerald Strengthens position of Unilife during ongoing commercial negotiations Facility has not been utilized to-date. No immediate intentions to do so Should Unilife elect to draw down on the facility in the future: No discount to
Slide 5: R&D Investment - Key to our Success
R&D Investment - Key to our Success November 8, 2012 Significant R&D investment across many areas: Customizing existing devices to address specific customer needs Continued pursuit of improving manufacturing efficiencies Development of additional device technologies Each program driven by a specific
Slide 6: LISA Reusable Auto-Injector
LISA(tm) Reusable Auto-Injector Select Injection Speed Push On Skin Sensor Single Activation Button Easy to Load Needle Free Removal The most advanced auto- injector, with everything a patient needs available at the push of a single button
Slide 7: Unilife Depot-Ject
Unilife Depot-Ject(tm) Precisely implants a drug depot into the target region of the patient's body using a standard one-handed injection technique
Slide 8: Unilife Ocu-Ject Platform
Unilife Ocu-Ject(tm) Platform November 8, 2012 Accurate, precise delivery microliter- sized doses to eye Intuitive, ergonomic features minimize pain to patient Optimize compliance with drug labels Prefilled with luer needle Fill at time of use Prefilled with retractable needle Multiple customization
Slide 9: Broad, Expanding Portfolio of Device Platforms
Broad, Expanding Portfolio of Device Platforms Ongoing R&D Investment
Slide 10: Financial Data Overview
Financial Data Overview Rich Wieland Chief Financial Officer
Slide 11: Financial Data
Financial Data 1Q 2013 1Q 2012 Revenues $ 0.7M $ 2.1M Research & development expense $ 4.7M $ 4.3M Selling, general & administrative expense $ 6.6M $ 6.2M Net loss $ 12.5M $ 9.7M Net loss per share - diluted $ (0.16) $ (0.16) Adjusted net loss $ 9.1M $ 6.5M Adjusted net loss per share - diluted $ (0
Slide 12: Improving Operating Expense Efficiencies
November 8, 2012 18.2% decrease in SG&A and R&D Improving Operating Expense Efficiencies
Slide 13: Commercial Update
Commercial Update Alan Shortall
Slide 14: Expanded Commercial Development Team
Expanded Commercial Development Team Michael Ratigan, Senior Vice President and Chief Commercial Officer 23 years of experience with life science and medical device companies Previously Commercial Development Director for Self-Administration of Injectable Systems at BD. Douglas Stout, Senior Directo
Slide 15: Bolus Injectors Targeted for Multi-Drug Program
Bolus Injectors Targeted for Multi-Drug Program Bolus Injectors Targeted for Multi-Drug Program November 8, 2012 Selected to enter next phase of collaboration with a global pharmaceutical company as its preferred choice for long-term subcutaneous drug delivery under a multi-drug program
Slide 16: Large Dose Volume Bolus Injection Systems
Large Dose Volume Bolus Injection Systems November 8, 2012 From 1mL - 30mL dose volumes Bolus or Rate-Based Therapies Standard Handling and Materials in Fluid Path Safe, Ergonomic and Intuitive Design Customization Options A flexible, scalable platform of wearable, disposable devices for the subcuta
Slide 17: Program with Global Pharmaceutical Company
Program with Global Pharmaceutical Company Targeted for Multi-Drug Program More than 5 target pipeline drugs First target in Phase III clinical trials Commenced initial device supply $10MM development agreement for 1st drug expected this fiscal year Expected commercial supply in 2015 Expected annual
Slide 18: Looking Forward
Looking Forward Targeted Delivery Systems Prefilled Syringes with Integrated Safety Drug Reconstitution Delivery Systems Auto-Injectors Bolus Injectors and Infusion Pumps Active commercial discussions occurring across all platforms Firm opportunities for agreements in all platforms 2012 - 2013
Slide 19: Questions
Questions November 8, 2012
Slide 20: Reminder: Annual Meeting of Stockholders
Reminder Annual Meeting of stockholders on Thursday November 29 at 4:00pm at the Intercontinental Barclay Hotel, New York All stockholders and CDI holders invited to attend Also broadcast on Unilife website as a 'live' listen only webcast Eligible stockholders should be receiving notice with instruc